Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Updates “Contact for Potential Acquisition of ' R&D Programs” Section on its Corporate Website

09/09/2021 | 08:12pm EDT

Astellas Pharma Inc. ('Astellas') updated the information about Astellas terminated R&D programs on 'Contact for Potential Acquisition of Astellas' R&D programs' section on its corporate website.

https://www.astellas.com/en/contact-r-and-d-programs

Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R&D that uses external resources and redevelopment for other indications. This endeavor is part of this effort, and the company is planning to post some of its terminated programs on the website successively to widely recruit potential parties. Through this, we hope to deliver new treatment options for patients suffering from diseases with high unmet medical needs.

Disclaimer

Astellas Pharma Inc. published this content on 10 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 September 2021 00:11:04 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
MT
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
10/05PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B round
DJ
10/05PRESS RELEASE : MIG Fonds leads EUR65 million Series B financing of iOmx Therapeutics
DJ
10/04PRESS RELEASE : MIG sells portfolio company Hemovent to MicroPort
DJ
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
PU
09/30ASTELLAS PHARMA : Corporate Strategic Plan 2021—dedicated to realization
PU
More news
Financials
Sales 2022 1 325 B 11 592 M 11 592 M
Net income 2022 194 B 1 701 M 1 701 M
Net cash 2022 478 B 4 178 M 4 178 M
P/E ratio 2022 18,9x
Yield 2022 2,50%
Capitalization 3 710 B 32 494 M 32 457 M
EV / Sales 2022 2,44x
EV / Sales 2023 2,07x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 2 002,00 JPY
Average target price 2 482,31 JPY
Spread / Average Target 24,0%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.25.60%31 970
JOHNSON & JOHNSON1.73%421 487
ROCHE HOLDING AG15.58%336 383
PFIZER, INC.12.52%233 631
NOVO NORDISK A/S51.58%230 493
ELI LILLY AND COMPANY40.19%214 579